Company: RGNX
Filing Date: 2025-04-08
Form Type: DEF 14A
Source: 0000950170-25-052069
Chunk: 64

Company: REGENXBIO Inc.
Filing Date: 2025-04-08
Form: DEF 14A
Chunk 64
---
 2024 was a Senior Scientist in our research and development organization.

After identifying our median employee, we calculated annual total compensation for the median employee using the same methodology we use for our named executive officers, as set forth in the Summary Compensation Table above. This process resulted in a median employee with annual total compensation of $226,641 for 2024.

We believe the pay ratio reported above is a reasonable estimate based on our internal records and the methodology described above. The SEC’s rules for identifying the median employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. As a result, the pay ratio reported by other companies may not be comparable to our pay ratio, as reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

<div align='center'>45</div>

Pay Versus Performance

The following table provides the total compensation, as reported in the Summary Compensation Table ("SCT"), and the compensation actually paid ("CAP") to our Principal Executive Officer ("PEO") and, on an average basis, our other NEOs ("non-PEO NEOs") for each of the years specified, alongside our total shareholder return ("TSR"), the TSR of our peers, our net income (loss) and a Company-selected financial performance measure of ending cash, cash equivalents and marketable securities. The Company selected ending cash, cash equivalents and marketable securities as the most important financial performance measure used to link compensation to performance in 2024 given its direct influence on our ability to maintain financial strength to achieve corporate objectives.

|      |     |                                       |     |                        |     |                                         |     |                          |     |                                       |     |                                   |     | Value of Initial Fixed $100 Investment Based On: |     |             |     |                      |     |                                                            |
| Year |     | SCT Total for PEO (Curran Simpson)(1) 
                                   ($) |     |             CAP to PEO 
 (Curran Simpson)(2)(3) 
                    ($) |     | SCT Total for PEO (Kenneth T. Mills)(1) 
                                     ($) |     |               CAP to PEO 
 (Kenneth T. Mills)(2)(4) 
                      ($) |     | Average SCT Total for Non-PEO NEOs(5)